Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005227235
Thu, 05.05.2022
Biotest AG
PRESS RELEASE
Biotest AG: Annual General Meeting approves dividend distribution
Distribution of EUR 0.04 per preferred share
Broad majority on all agenda items in accordance with the proposals of the management (Verwaltung)
Dreieich 05 May 2022. At the third ordinary, virtual Annual General Meeting on 05 May 2022, the shareholders of Biotest AG [ … ]
Thu, 05.05.2022
Biotest AG
PRESS RELEASEBiotest records sales of € 115 million in the first quarter of 2022
EBIT increase compared to the first quarter of 2021
EBIT includes Biotest Next Level expenses of € -20.3 million
Biotest signs license agreement for its novel immunoglobulin (IgG Next Generation)
Dreieich, 05 May, 2022. The Biotest Group recorded revenue of € 115.9 [ … ]
Mon, 02.05.2022
Biotest AG
PRESS RELEASE
Biotest Supervisory Board appoints new Management Board member
Peter Janssen will succeed Dr Georg Floß as Chief Operations Officer (COO) end of the year
Dreieich, 2 Mai 2022. At its meeting on April 12th, the Supervisory Board of Biotest AG appointed Peter Janssen (55) as a further member of the company's Management Board with effe [ … ]
Mon, 25.04.2022
Biotest AG
PRESS RELEASE
Grifols acquires majority of voting rights in Biotest
Admission of all offer conditions
Transfer of tendered shares completed
Majority shareholding of Grifols in Biotest (96.2% of the ordinary voting shares of Biotest AG)
Board of Management welcomes the takeover
Dreieich, 25 April 2022. On 12 April 2022, Biotest AG notified tha [ … ]
Thu, 07.04.2022
Biotest AG
PRESS RELEASE
Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement
First submission for product from the new Biotest Next Level production facility
Approval expected in 4th quarter
Signature of first licensing agreement
Dreieich, 7 April 2022. Biotest AG announced today that the market [ … ]
Thu, 24.03.2022
Biotest AG
PRESS RELEASE
Biotest exceeds sales guidance in fiscal year 2021
Revenue increase of 6.5%
EBIT in core business profitable at €29.4 million
Biotest invites to the virtual Annual General Meeting on May 5, 2021
Dreieich, March 24, 2022. In fiscal year 2021, the Biotest Group generated revenues of € 515.6 million, compared to € 484.2 million in th [ … ]
Thu, 10.03.2022
Biotest AG
PRESS RELEASE
Biotest AG opens ninth plasma collection centre in Czech Republic
- 29 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 10 March 2022. Biotest has received the operating license for its ninth plasma collection centre in Czech Republic from the country's national public health authority SUKL.
The cent [ … ]
Wed, 16.02.2022
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest exceeds Revenue guidance 2021Dreieich, 16 February 2022. According to preliminary and not yet audited figures, Biotest AG increased its revenues by more than 6.5 % to € 515.6 million in fiscal year 2021, compared to € 484.2 million in the previous year [ … ]
Tue, 18.01.2022
Biotest AG
PRESS RELEASE
Biotest combats climate change through CO2-neutral production
Climate neutrality achieved at the Dreieich site
Electricity purchased from renewable sources
Continuous reduction of energy consumption through targeted investments
Dreieich, 18 January 2022. Biotest AG is actively involved in the fight against climate change at the Dr [ … ]
Wed, 12.01.2022
Biotest AG
PRESS RELEASE
Biotest AG opens eighth plasma collection centre in Czech Republic
28 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 12 January 2022. Biotest has received the operating license for its eighth plasma collection centre in Czech Republic from the country's national public health authority SUKL. The cent [ … ]